Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Video Presentation on Management Options for Stage IIIA NSCLC
Dr West
With special thanks to the support of the Lung Cancer Connection and longtime member and friend of GRACE Myrtle Chidester, I am very happy to offer a new video podcast presentation on one of the most controversial and interesting areas of lung cancer management. Stage IIIA NSCLC with N2 mediastinal node involvement generates debates among the experts as well as at local hospital tumor boards everywhere, on a weekly basis. There is a little bit of evidence to support several views of how best to treat such patients, while in fact there is a lot of hoterogeneity within the stage IIIA N2 population. For this reason, we often manage people on a case by case basis, which may well be the optimal strategy after all.
Here is a general summary of the current state of the field. Below is the link to the audio version, the transcript and figures, and the video version at the bottom.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
This live virtual event, led by Dr. Andrew Srisuwananukorn on October 25, 2025, brought together top oncologists to share the latest updates in blood cancer treatment. The program featured patient-focused presentations, expert panel discussions, and a real-time Q&A session where attendees could engage directly with specialists.
To watch the complete playlist, click here.
Image
Video
In this video series led by Dr. Siddharth Sheth and recorded on October 27, 2025, a panel of leading oncologists engages in a dynamic and insightful roundtable discussion as they share newly released data, key highlights, and significant developments in head and neck cancer treatment while addressing the most pressing questions, delivered in a concise and easy-to-understand format.
To watch the complete playlist, click here.
Image
Video
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.
In this 2nd series of videos, Michael Herman takes us through the story of his diagnosis, his struggles with treatment options, his clinical trial and his learning curve.
Thank you to our Sponsors! #lilly #exelixis
Online Community
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.